tariff relief

Regeneron agrees with Trump Administration to lower drug prices via Medicaid benchmarking and free gene therapy access, receiving three years of tariff relief and regulatory certainty.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Supreme Court voids Trump's tariffs in 6-3 decision. Tech and consumer stocks poised to benefit from lower costs, while domestic manufacturers face increased competition.